pancreatic cancer

[Cellular Oncology] Investigators identified the prognostic significance and therapeutic options of metabolic subtypes of resectable pancreatic cancer.

[Bioengineered] Higd-1a promotes the proliferation of pancreatic cancer cells and the growth of pancreatic cancer; however, no similar observations have been reported for colorectal cancer (CRC). This study, researchers verified the role of Higd-1a in colorectal cancer.

[Oncology Reports] Scientists examined the expression of miR‑190b in pancreatic cancer cell lines and tissues and evaluated its effects on cancer progression.

[Cend Therapeutics, Inc. (GlobeNewswire, Inc.)] Patient dosing has begun in a Phase Ib/IIa clinical trial to evaluate the safety, tolerability and pharmacologic activity of CEND-1, an investigational drug that modifies the tumor microenvironment, in pancreatic, appendiceal and colon cancers in collaboration with the University of Kansas Cancer Center.

[Laboratory Investigation] Investigators evaluated the radiosensitizing and anti-RIF potential of fluvastatin in pancreatic cancer (PC). Short-term viability and clonogenic survival assays were used to evaluate the radiosensitizing potential of fluvastatin in multiple human and murine PC cell lines.

[Molecules] Scientists investigated whether the autophagy inhibitor chloroquine could potentiate the anticancer effect of pterostilbene in the PDAC cell lines MIA PaCa-2 and BxPC-3, as well as in an orthotopic animal model.